Susan Boyce

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.

S. Boyce, C. Brideau, A. Ford-hutchinson, 1995, The Journal of pharmacology and experimental therapeutics.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

M. Percival, D. Riendeau, B. Kennedy, 1999, Bioorganic & medicinal chemistry letters.

Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats

S. Boyce, R. Hill, S. Shepheard, 2000, Pain.

Antinociceptive activity of NK1 receptor antagonists: non‐specific effects of racemic RP67580

S. Iversen, S. Boyce, G. Seabrook, 1993, British journal of pharmacology.

L-745,337: A selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats

S. Boyce, R. Gordon, I. Rodger, 1994, Neuropharmacology.

Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo

J. Bilsland, S. Boyce, L. Young, 1999, Neuroscience.

Neurological phenotype and synaptic function in mice lacking the CaV1.3 α subunit of neuronal L-type voltage-dependent Ca2+ channels

F. Kuenzi, D. Kullmann, S. Boyce, 2003, Neuroscience.